New findings highlight the importance of C-reactive protein-driven patient selection for corticosteroid therapy in pneumonia.

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Harrow (HROW) announced the execution of a five-year strategic supply and development agreement for Triesence 40 mg/mL, a preservative-free ...

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...

Intra-articular corticosteroid injection is associated with a reduced use of pain medications, including opioid combinations, ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Even with recommendations in place, hospitals were far from uniform in their anticoagulation approaches well into 2022.

For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) ...

Introduction Despite advancements in asthma management, many patients continue to experience poor disease control, lung function decline, and frequent exacerbations. Clinical remission (CR) has been ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 and beyond.